Compare Amylx Pharmaceuticals Inc (AMLX) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Ferrari NV — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Ferrari NV trades at $405.1 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 27.1× Amylx Pharmaceuticals Inc's market cap, and Ferrari NV pays a 1.04% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | RACE | |
|---|---|---|
Market Cap | $2.64B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $504.09 |
52-Week Low | $7.82 | $314.63 |
Enterprise Value | $2.39B | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
Ferrari (RACE) trades at $407.21, up 0.11% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, with 2025 revenue at $7.15 billion and net income margin of 22.25%, though valuation multiples like P/E of 37.93 are elevated.
The outlook remains positive given earnings beats, raised guidance, and analyst consensus favoring buys, but risks include high valuation sensitivity and economic cyclicality. Upside to the $462.67 price target depends on sustained premium demand execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
